Cutia Therapeutics (HK:2487) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cutia Therapeutics has received marketing approval from China’s National Medical Products Administration for its topical 4% minocycline foam, CU-10201, designed to treat moderate to severe acne vulgaris. This is the first topical minocycline approved globally, offering benefits like lower systemic exposure and fewer side effects compared to oral medications. The approval follows promising Phase III clinical trial results indicating significant efficacy and safety.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.